Costs to australian taxpayers of pharmaceutical monopolies and proposals to extend them in the Trans-Pacific partnership agreement
Intellectual property (IP) protections proposed by the United States for the Trans-Pacific Partnership Agreement (TPPA) have sparked widespread alarm about the potential negative impact on access to affordable medicines. The most recently leaked draft of
|Collections||ANU Research Publications|
|Source:||Medical Journal of Australia|
|01_Gleeson_Costs_to_australian_taxpayers_2015.pdf||110.4 kB||Adobe PDF|
Items in Open Research are protected by copyright, with all rights reserved, unless otherwise indicated.